Enter your email address below and subscribe to our newsletter

Treatments & Surgery

Share your love

Nicox Concludes U.S. Recruitment for Phase 3 NCX 470 Trial

Nicox announced the recruitment and randomization of the final patient in the United States for its Denali Phase 3 trial of NCX 470. This milestone marks a significant step in evaluating the safety and efficacy of NCX 470 for patients…

Glaukos Activates CMS J-Code for iDose TR

Glaukos Corporation has confirmed the activation of the CMS Healthcare Common Procedure Coding System’s J-code—J7355—for its iDose TR product. This development marks a significant milestone in enhancing patient access and streamlining coverage and payment processes for the innovative treatment, according…

Alcon Finalizes Acquisition of BELKIN Vision

Alcon has finalized its acquisition of BELKIN Vision, marking a significant expansion of its glaucoma treatment offerings. The acquisition, valued at $81M upfront, with potential additional payments up to $385M contingent on sales milestones, includes BELKIN Vision’s innovative Direct Selective…

What Is Symblepharon? | OBN

What Is Symblepharon? Symblepharon is a medical condition characterized by the adhesion of the conjunctiva, the clear membrane that covers the white part of the eye and the inside of the eyelids, to the cornea, the clear front part of…

Top 10 Ophthalmologists Who Changed the Field

Ophthalmology, the branch of medicine that deals with the diagnosis and treatment of eye-related diseases and disorders, has made great strides in the past century. The following ten individuals are among the most influential and accomplished ophthalmologists in history, each…

Antibiotics Help Prevent Infections in Cataract Patients

A recent study published in JAMA Ophthalmology has highlighted the effectiveness of selective intracameral antibiotics combined with 1% povidone iodine in reducing the incidence of postoperative endophthalmitis after cataract surgery. Led by Jeroen van Rooij, MD, from Rotterdam Eye Hospital,…

Thea Pharma’s New Website for Iyuzeh Support

Thea Pharmaceuticals launched a new website aimed at providing comprehensive resources to ophthalmologists for the effective use of latanoprost ophthalmic solution 0.005%, marketed as Iyuzeh, in patient care. This initiative comes in response to feedback from Eye Care Professionals (ECPs)…

Stay informed and not overwhelmed, subscribe now!